SG Americas Securities LLC Boosts Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

SG Americas Securities LLC lifted its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 78.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 57,566 shares of the company’s stock after acquiring an additional 25,247 shares during the period. SG Americas Securities LLC’s holdings in Lyell Immunopharma were worth $79,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of Lyell Immunopharma in the 1st quarter valued at $191,000. Acadian Asset Management LLC purchased a new position in shares of Lyell Immunopharma in the 1st quarter worth $173,000. TD Asset Management Inc boosted its holdings in Lyell Immunopharma by 4.2% in the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after acquiring an additional 40,800 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Lyell Immunopharma by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after acquiring an additional 69,712 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma during the first quarter worth about $64,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Monday.

Lyell Immunopharma Stock Up 1.0 %

Lyell Immunopharma stock opened at $0.94 on Tuesday. The firm has a fifty day moving average of $1.29 and a 200-day moving average of $1.79. Lyell Immunopharma, Inc. has a 52-week low of $0.86 and a 52-week high of $3.26. The firm has a market capitalization of $238.62 million, a P/E ratio of -1.04 and a beta of -0.53.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. On average, research analysts expect that Lyell Immunopharma, Inc. will post -0.85 EPS for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.